Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma.
Background: Cabergoline is a Dopamine 2 receptor agonist. Corticotroph adenoma has shown to have the D2 receptor in in vitro studies.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor|
- Response in term of mid night cortisol < 5.0 mcg/dl and/or Standard two day dexamethasone suppression test < 1.8 mcg/dl
|Study Start Date:||November 2007|
Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00889525
|Seth GSMC & KEM hospital|
|Mumbai, Maharashtra, India, 4000012|
|Principal Investigator:||Nalini S Shah, DM||Seth GSMC and KEM hospital, Mumbai|